Safety of a thickened extensive casein hydrolysate formula

Autor: Vandenplas, Yvan, De Greef, Elisabeth, Xinias, I, Vrani, O, Mavroudi, A, Hammoud, M, Al Refai, F, Khalife, M C, Sayad, A, Noun, P, Farah, A, Makhoul, G, Orel, R, Sokhn, M, L'Homme, A, Mohring, M P, Merhi, B Abou, Boulos, J, El Masri, H, Halut, C, Allar Study Group
Přispěvatelé: Growth and Development, Clinical sciences, Faculty of Medicine and Pharmacy
Rok vydání: 2015
Předmět:
0301 basic medicine
(Extensive) hydrolysate
Dietary Fiber
Male
Allergy
Pediatrics
thickened formula
Protein Hydrolysates
Endocrinology
Diabetes and Metabolism
Milk allergy
Gastroenterology
Cow's milk allergy
Infant nutrition
0302 clinical medicine
Child Development
Hydrolyzed protein formula
Casein
Prospective Studies
health care economics and organizations
education.field_of_study
Nutrition and Dietetics
Viscosity
Caseins
humanities
Infant Formula
Milk
Female
Dietary Proteins
medicine.medical_specialty
Population
antiregurgitation formula
Hydrolysate
03 medical and health sciences
Double-Blind Method
030225 pediatrics
Internal medicine
medicine
Dietary Carbohydrates
Laryngopharyngeal Reflux
Animals
Humans
education
030109 nutrition & dietetics
business.industry
Body Weight
Infant
Hypoallergenic
Immunoglobulin E
medicine.disease
Dietary Fats
Body Height
Infant formula
Milk Hypersensitivity
business
Energy Intake
Zdroj: Nutrition (Burbank, Los Angeles County, Calif.). 32(2)
ISSN: 1873-1244
Popis: Objectives Cow's milk allergy (CMA) is treated in formula-fed infants with an extensive protein hydrolysate. This study aimed to evaluate the nutritional safety of a non-thickened and thickened extensively casein hydrolyzed protein formula (NT- and T-eCHF) in infants with CMA. Methods Infants younger than 6 mo old with a positive cow milk challenge test, positive IgE, or skin prick test for cow milk were selected. Weight and length were followed during the 6 mo intervention with the NT-eCHF and T-eCHF. Results A challenge was performed in 50/71 infants with suspected CMA and was positive in 34/50. All children with confirmed CMA tolerated the eCHF. The T-eCHF leads to a significant improvement of the stool consistency in the whole population and in the subpopulation of infants with proven CMA. Height and weight evolution was satisfactory throughout the 6 mo study. Conclusions The eCHF fulfills the criteria of a hypoallergenic formula and the NT- and T-eCHF reduced CMA symptoms. Growth was within normal range.
Databáze: OpenAIRE
Externí odkaz: